This article is more than 5 years old. Information may no longer be current.

FDA grants marketing approval for generic Lumigan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Lupin Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration to market a generic version of Allergan’s Lumigan in the U.S.

This approval to market bimatoprost ophthalmic solution 0.03% follows a January FDA audit of the company’s Indore, India, facility where the product was made, according to a company press release.

The AT-rated generic is indicated for reduction of elevated IOP in the treatment of open angle glaucoma or ocular hypertension.